Key facts
- This page summarizes Ultragenyx Pharmaceutical Inc.'s Form 4 filing for Arcturus Therapeutics Holdings Inc. (ARCT).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 12 Aug 2021, 17:11.
Ultragenyx Pharmaceutical Inc. - 10 Aug 2021 Form 4 Insider Report for Arcturus Therapeutics Holdings Inc. (ARCT)
- Reporting relationship
- Director
- Issuer ticker
- ARCT
- Reported as of
- 10 Aug 2021
- Net transaction value
- -$43,631,250
- Reporting owner signature
- /s/ Mardi C. Dier, EVP and Chief Financial Officer
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Ultragenyx Pharmaceutical Inc. filed Form 4 for Arcturus Therapeutics Holdings Inc. (ARCT) on 12 Aug 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$43,631,250.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ARCT
transaction
Common Stock
Sale
- Transaction value
- -$40,194,000
- Shares
- -725,000
- Change %
- -33%
- Price
- $55.44
- Shares after
- 1,475,000
- Date
- 10 Aug 2021
- Ownership
- Direct
- Footnotes
- F1
ARCT
transaction
Common Stock
Sale
- Transaction value
- -$3,437,250
- Shares
- -75,000
- Change %
- -5.1%
- Price
- $45.83
- Shares after
- 1,400,000
- Date
- 11 Aug 2021
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $64.75 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $47.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.